Abstract
Chronic or persistent human papillomavirus (HPV) infection is essential for the development of many types of carcinomas, such as cervical carcinoma. Developing new diagnostic and prognostic biomarkers and designing more effective targeted therapeutics and treatment strategies remains urgent. Numerous efforts have been made to design new drugs and vaccines to treat HPV infections. Due to the special HPV infection pathway, entry inhibitors to block viral entry into target cells have been extensively and deeply studied. This chapter reviews the basic characteristics of HPV infection and the various types of HPV entry inhibitors, which were found to have high safety, potent antiviral effects, and broad-spectrum activity against multiple HPV subtypes. Together with the use of prophylactic vaccines, the development and application of these entry inhibitors will reduce the incidence of HPV infection and associated cancers in the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aksoy P, Gottschalk EY, Meneses PI (2017) HPV entry into cells. Mutat Res Rev Mutat Res 772:13–22. https://doi.org/10.1016/j.mrrev.2016.09.004
Andersen JH, Jenssen H, Gutteberg TJ (2003) Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res 58(3):209–215. https://doi.org/10.1016/S0166-3542(02)00214-0
Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000) The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 74(24):11636–11641. https://doi.org/10.1128/Jvi.74.24.11636-11641.2000
Baleja JD, Cherry JJ, Liu Z, Gao H, Nicklaus MC, Voigt JH, Chen JJ, Androphy EJ (2006) Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res 72(1):49–59. https://doi.org/10.1016/j.antiviral.2006.03.014
Beadle JR, Valiaeva N, Yang G, Yu JH, Broker TR, Aldern KA, Harden EA, Keith KA, Prichard MN, Hartman T, Buckheit RW Jr, Chow LT, Hostetler KY (2016) Synthesis and antiviral evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a potent inhibitor of transient HPV DNA amplification. J Med Chem 59(23):10470–10478. https://doi.org/10.1021/acs.jmedchem.6b00659
Bell JA, Sundberg JP, Ghim SJ, Newsome J, Jenson AB, Schlegel R (1994) A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. Pathobiology 62(4):194–198. https://doi.org/10.1159/000163910
Bergvall M, Melendy T, Archambault J (2013) The E1 proteins. Virology 445(1-2):35–56. https://doi.org/10.1016/j.virol.2013.07.020
Berkhout B, van Wamel JL, Beljaars L, Meijer DK, Visser S, Floris R (2002) Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res 55(2):341–355. https://doi.org/10.1016/s0166-3542(02)00069-4
Bissett SL, Godi A, Beddows S (2016) The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. Sci Rep 6:39730. https://doi.org/10.1038/srep39730
Booy FP, Roden RB, Greenstone HL, Schiller JT, Trus BL (1998) Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol 281(1):95–106. https://doi.org/10.1006/jmbi.1998.1920
Borgogna C, Zavattaro E, De Andrea M, Griffin HM, Dell’Oste V, Azzimonti B, Landini MM, Peh WL, Pfister H, Doorbar J, Landolfo S, Gariglio M (2012) Characterization of beta papillomavirus E4 expression in tumours from Epidermodysplasia Verruciformis patients and in experimental models. Virology 423(2):195–204. https://doi.org/10.1016/j.virol.2011.11.029
Bousarghin L, Touze A, Yvonnet B, Coursaget P (2004) Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity. J Med Virol 73(3):474–480. https://doi.org/10.1002/jmv.20114
Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR (1995) Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69(6):3959–3963. https://doi.org/10.1128/JVI.69.6.3959-3963.1995
Buck CB, Trus BL (2012) The papillomavirus virion: a machine built to hide molecular Achilles’ heels. Adv Exp Med Biol 726:403–422. https://doi.org/10.1007/978-1-4614-0980-9_18
Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT (2005) Maturation of papillomavirus capsids. J Virol 79(5):2839–2846. https://doi.org/10.1128/JVI.79.5.2839-2846.2005
Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT (2006a) Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 103(5):1516–1521. https://doi.org/10.1073/pnas.0508033103
Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT (2006b) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2(7):e69. https://doi.org/10.1371/journal.ppat.0020069
Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82(11):5190–5197. https://doi.org/10.1128/JVI.02726-07
Bzhalava D, Eklund C, Dillner J (2015) International standardization and classification of human papillomavirus types. Virology 476:341–344. https://doi.org/10.1016/j.virol.2014.12.028
Campos-Leon K, Wijendra K, Siddiqa A, Pentland I, Feeney KM, Knapman A, Davies R, Androphy EJ, Parish JL (2017) Association of human papillomavirus 16 E2 with Rad50-interacting Protein 1 enhances viral DNA replication. J Virol 91(5). https://doi.org/10.1128/JVI.02305-16
Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5(3):557–567. https://doi.org/10.1016/s1097-2765(00)80449-9
Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA, Zaneveld LJ (2001) Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 45(12):3427–3432. https://doi.org/10.1128/AAC.45.12.3427-3432.2001
Cruz L, Meyers C (2013) Differential dependence on host cell glycosaminoglycans for infection of epithelial cells by high-risk HPV types. PLoS One 8(7):e68379. https://doi.org/10.1371/journal.pone.0068379
Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA (2021) Persistent human papillomavirus infection. Viruses 13(2). https://doi.org/10.3390/v13020321
Ding Y, Wen J, Lai B, Liu S, Li L (2018) Caffeic acid has activity against the human papillomavirus. Chin J Virol 34(03):8
Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110(5):525–541. https://doi.org/10.1042/CS20050369
Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I (2015) Human papillomavirus molecular biology and disease association. Rev Med Virol 25(Suppl 1):2–23. https://doi.org/10.1002/rmv.1822
Drobni P, Naslund J, Evander M (2004) Lactoferrin inhibits human papillomavirus binding and uptake in vitro. Antiviral Res 64(1):63–68. https://doi.org/10.1016/j.antiviral.2004.05.005
Fahey LM, Raff AB, Da Silva DM, Kast WM (2009) A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol 183(10):6151–6156. https://doi.org/10.4049/jimmunol.0902145
Fast LA, Mikulicic S, Fritzen A, Schwickert J, Boukhallouk F, Hochdorfer D, Sinzger C, Suarez H, Monk PN, Yanez-Mo M, Lieber D, Florin L (2018) Inhibition of tetraspanin functions impairs human papillomavirus and cytomegalovirus infections. Int J Mol Sci 19(10):307. https://doi.org/10.3390/ijms19103007
Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS, Williams K, Duerksen-Hughes PJ (2007) The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 81(8):4116–4129. https://doi.org/10.1128/JVI.01924-06
Frazer IH (2014) Development and implementation of papillomavirus prophylactic vaccines. J Immunol 192(9):4007–4011. https://doi.org/10.4049/jimmunol.1490012
Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81(24):13927–13931. https://doi.org/10.1128/JVI.00936-07
Gao Y, Liu W, Wang W, Zhang X, Zhao X (2018) The inhibitory effects and mechanisms of 3,6-O-sulfated chitosan against human papillomavirus infection. Carbohydr Polym 198:329–338. https://doi.org/10.1016/j.carbpol.2018.06.096
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA, Females United to Unilaterally Reduce Endo/Ectocervical Disease II (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943. https://doi.org/10.1056/NEJMoa061760
Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75(3):1565–1570. https://doi.org/10.1128/JVI.75.3.1565-1570.2001
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D (2011) Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 364(5):401–411. https://doi.org/10.1056/NEJMoa0909537
Gloss B, Bernard HU (1990) The E6/E7 promoter of human papillomavirus type 16 is activated in the absence of E2 proteins by a sequence-aberrant Sp1 distal element. J Virol 64(11):5577–5584. https://doi.org/10.1128/JVI.64.11.5577-5584.1990
Gräßel L, Fast LA, Scheffer KD, Boukhallouk F, Spoden GA, Tenzer S, Boller K, Bago R, Rajesh S, Overduin M, Berditchevski F, Florin L (2016) The CD63-Syntenin-1 complex controls post-endocytic trafficking of oncogenic human papillomaviruses. Sci Rep 6(1):32337. https://doi.org/10.1038/srep32337
Group FIS (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927. https://doi.org/10.1056/NEJMoa061741
Guan J, Bywaters SM, Brendle SA, Lee H, Ashley RE, Makhov AM, Conway JF, Christensen ND, Hafenstein S (2015) Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology 483:253–263. https://doi.org/10.1016/j.virol.2015.04.016
Guo X, Qiu L, Wang Y, Wang Y, Meng Y, Zhu Y, Lu L, Jiang S (2016a) Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. J Med Virol 88(6):1098–1101. https://doi.org/10.1002/jmv.24439
Guo X, Qiu L, Wang Y, Wang Y, Wang Q, Song L, Li Y, Huang K, Du X, Fan W, Jiang S, Wang Q, Li H, Yang Y, Meng Y, Zhu Y, Lu L, Jiang S (2016b) A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. Microbes Infect 18(2):148–152. https://doi.org/10.1016/j.micinf.2015.10.004
Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H (2002) Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24(3):228. https://doi.org/10.1016/s1386-6346(02)00088-8
Hebner CM, Laimins LA (2006) Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16(2):83–97. https://doi.org/10.1002/rmv.488
Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R, Group CVT (2014) Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 32(39):5087–5097. https://doi.org/10.1016/j.vaccine.2014.06.038
Hua C, Zhu Y, Wu C, Si L, Wang Q, Sui L, Jiang S (2019) The underlying mechanism of 3-Hydroxyphthalic anhydride-modified bovine beta-lactoglobulin to block human papillomavirus entry into the host cell. Front Microbiol 10:2188. https://doi.org/10.3389/fmicb.2019.02188
Jarrett WF, O’Neil BW, Gaukroger JM, Laird HM, Smith KT, Campo MS (1990) Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet Rec 126(18):449–452
Johnson JA, Gangemi JD (1999) Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 43(5):1198–1205. https://doi.org/10.1128/AAC.43.5.1198
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPVVS (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372(8):711–723. https://doi.org/10.1056/NEJMoa1405044
Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274(9):5810–5822. https://doi.org/10.1074/jbc.274.9.5810
Kilmarx PH, van de Wijgert JH, Chaikummao S, Jones HE, Limpakarnjanarat K, Friedland BA, Karon JM, Manopaiboon C, Srivirojana N, Yanpaisarn S, Supawitkul S, Young NL, Mock PA, Blanchard K, Mastro TD (2006) Safety and acceptability of the candidate microbicide Carraguard in Thai Women: findings from a Phase II Clinical Trial. J Acquir Immune Defic Syndr 43(3):327–334. https://doi.org/10.1097/01.qai.0000243056.59860.c1
Kokuba H, Aurelian L, Neurath AR (1998) 3-Hydroxyphthaloyl beta-lactoglobulin. IV antiviral activity in the mouse model of genital herpesvirus infection. Antivir Chem Chemother 9(4):353–357
Lembo D, Donalisio M, Rusnati M, Bugatti A, Cornaglia M, Cappello P, Giovarelli M, Oreste P, Landolfo S (2008) Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob Agents Chemother 52(4):1374–1381. https://doi.org/10.1128/AAC.01467-07
Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, Kleinbeck K, Bonnaire T, Robbiani M, Zydowsky TM, O’Keefe BR, Fernandez-Romero JA (2015) Griffithsin and Carrageenan combination to target herpes simplex virus 2 and human papillomavirus. Antimicrob Agents Chemother 59(12):7290–7298. https://doi.org/10.1128/AAC.01816-15
Liu X, Chen J, Wang Z, Wang D, He M, Qian C, Song S, Chi X, Kong Z, Zheng Q, Wang Y, Yu H, Zhao Q, Zhang J, Li S, Gu Y, Xia N (2019a) Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. Emerg Microbes Infect 8(1):1721–1733. https://doi.org/10.1080/22221751.2019.1694396
Liu Y, Li H, Pi R, Yang Y, Zhao X, Qi X (2019b) Current strategies against persistent human papillomavirus infection (Review). Int J Oncol 55(3):570–584. https://doi.org/10.3892/ijo.2019.4847
Longworth MS, Laimins LA (2004) The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 78(7):3533–3541. https://doi.org/10.1128/jvi.78.7.3533-3541.2004
Lu L, Yang X, Li Y, Jiang S (2013) Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. Microbes Infect 15(6-7):506–510. https://doi.org/10.1016/j.micinf.2013.03.003
Magnan S, Tota JE, El-Zein M, Burchell AN, Schiller JT, Ferenczy A, Tellier PP, Coutlee F, Franco EL, Group CS (2019) Efficacy of a carrageenan gel against transmission of cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. Clin Microbiol Infect 25(2):210–216. https://doi.org/10.1016/j.cmi.2018.04.012
Mallon RG, Wojciechowicz D, Defendi V (1987) DNA-binding activity of papillomavirus proteins. J Virol 61(5):1655–1660. https://doi.org/10.1128/JVI.61.5.1655-1660.1987
de Martel C, Plummer M, Vignat J, Franceschi S (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141(4):664–670. https://doi.org/10.1002/ijc.30716
Mauro N, Ferruti P, Ranucci E, Manfredi A, Berzi A, Clerici M, Cagno V, Lembo D, Palmioli A, Sattin S (2016) Linear biocompatible glyco-polyamidoamines as dual action mode virus infection inhibitors with potential as broad-spectrum microbicides for sexually transmitted diseases. Sci Rep 6:33393. https://doi.org/10.1038/srep33393
McBride AA (2013) The papillomavirus E2 proteins. Virology 445(1-2):57–79. https://doi.org/10.1016/j.virol.2013.06.006
McLaughlin-Drubin ME, Bromberg-White JL, Meyers C (2005) The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 338(1):61–68. https://doi.org/10.1016/j.virol.2005.04.036
Mistry N, Drobni P, Naslund J, Sunkari VG, Jenssen H, Evander M (2007) The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res 75(3):258–265. https://doi.org/10.1016/j.antiviral.2007.03.012
Modis Y, Trus BL, Harrison SC (2002) Atomic model of the papillomavirus capsid. EMBO J 21(18):4754–4762. https://doi.org/10.1093/emboj/cdf494
Neurath AR, Debnath AK, Strick N, Li YY, Lin K, Jiang S (1995) Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J Mol Recognit 8(5):304–316. https://doi.org/10.1002/jmr.300080504
Neurath AR, Li YY, Strick N, Jiang S (1996) A herpesvirus inhibitor from bovine whey. Lancet 347(9016):1703–1704
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, Group HPs (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369(9580):2161–2170. https://doi.org/10.1016/S0140-6736(07)60946-5
Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA, Coleman N (2004) Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 64(4):1359–1368. https://doi.org/10.1158/0008-5472.can-03-3214
Pierceall WE, Goldberg LH, Ananthaswamy HN (1991) Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers. J Invest Dermatol 97(5):880–884. https://doi.org/10.1111/1523-1747.ep12491612
Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P, Superti F (2006) Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res 69(2):98–106. https://doi.org/10.1016/j.antiviral.2005.10.006
Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM (2013) The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol 87(11):6062–6072. https://doi.org/10.1128/JVI.00330-13
Rautava J, Syrjanen S (2012) Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol 6(Suppl 1):S3–S15. https://doi.org/10.1007/s12105-012-0367-2
Richards RM, Lowy DR, Schiller JT, Day PM (2006) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103(5):1522–1527. https://doi.org/10.1073/pnas.0508815103
Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13(7):857–861. https://doi.org/10.1038/nm1598
Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, Berditchevski F, Florin L (2013) Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol 87(6):3435–3446. https://doi.org/10.1128/JVI.02906-12
Senapati R, Senapati NN, Dwibedi B (2016) Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer 11:59. https://doi.org/10.1186/s13027-016-0107-4
Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R (2003) Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 77(24):13125–13135. https://doi.org/10.1128/jvi.77.24.13125-13135.2003
van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK (2001) Antiviral activities of lactoferrin. Antiviral Res 52(3):225–239. https://doi.org/10.1016/s0166-3542(01)00195-4
Tommasino M (2014) The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 26:13–21. https://doi.org/10.1016/j.semcancer.2013.11.002
Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, Vanden Houte K, Reynders M, Snoeck R, Bossens M (2009) Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115(1):69–74. https://doi.org/10.1016/j.ygyno.2009.06.042
Vashisht S, Mishra H, Mishra PK, Ekielski A, Talegaonkar S (2019) Structure, genome, infection cycle and clinical manifestations associated with human papillomavirus. Curr Pharm Biotechnol 20(15):1260–1280. https://doi.org/10.2174/1389201020666190802115722
Wang JW, Roden RB (2013) L2, the minor capsid protein of papillomavirus. Virology 445(1-2):175–186. https://doi.org/10.1016/j.virol.2013.04.017
Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM (2011) Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol 85(16):8080–8092. https://doi.org/10.1128/JVI.00670-11
Westra WH, Lewis JS Jr (2017) Update from the 4th edition of the World Health Organization Classification of head and neck tumours: oropharynx. Head Neck Pathol 11(1):41–47. https://doi.org/10.1007/s12105-017-0793-2
White PW, Titolo S, Brault K, Thauvette L, Pelletier A, Welchner E, Bourgon L, Doyon L, Ogilvie WW, Yoakim C, Cordingley MG, Archambault J (2003) Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J Biol Chem 278(29):26765–26772. https://doi.org/10.1074/jbc.M303608200
White PW, Faucher AM, Massariol MJ, Welchner E, Rancourt J, Cartier M, Archambault J (2005) Biphenylsulfonacetic acid inhibitors of the human papillomavirus type 6 E1 helicase inhibit ATP hydrolysis by an allosteric mechanism involving tyrosine 486. Antimicrob Agents Chemother 49(12):4834–4842. https://doi.org/10.1128/AAC.49.12.4834-4842.2005
Wiens ME, Smith JG (2015) Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection. J Virol 89(5):2866–2874. https://doi.org/10.1128/JVI.02901-14
Wilkinson D, Tholandi M, Ramjee G, Rutherford GW (2002) Nonoxynol-9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infect Dis 2(10):613–617. https://doi.org/10.1016/s1473-3099(02)00396-1
Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM (2012) The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7(8):e43519. https://doi.org/10.1371/journal.pone.0043519
Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM (2015) Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother 70(6):1686–1690. https://doi.org/10.1093/jac/dkv045
World Health Organization (2017) Human papillomavirus vaccines: WHO position paper, May 2017–recommendations. Vaccine 35(43):5753–5755
World Health Organization (2020) Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. International Agency for Research on Cancer Geneva, World Health Organization, Geneva
Yan H, Foo SS, Chen W, Yoo JS, Shin WJ, Wu C, Jung JU (2019) Efficient inhibition of human papillomavirus infection by l2 minor capsid-derived lipopeptide. mBio 10(4):e01834–e01819. https://doi.org/10.1128/mBio.01834-19
Ying C, Wang T, Hong W (2016) Clinical effect of anti-HPV biological protein dressing in the treatment of cervical high risk HPV infection. Chin Comm Doctors 32(26):77–78. https://doi.org/10.3969/j.issn.1007-614x.2016.26.46
Zhang X, Li S, Modis Y, Li Z, Zhang J, Xia N, Zhao Q (2016) Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Rev Med Virol 26(2):115–128. https://doi.org/10.1002/rmv.1867
Zhang Y, Wang J, Chen X (2018) Observation on the effect of vaginal administration of anti-HPV biological protein dressing in the treatment of HPV high-risk infection complicated with CINI. Clin Med Eng 25(12):1647–1648. https://doi.org/10.3969/j.issn.1674-4659.2018.12.1647
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2(5):342–350. https://doi.org/10.1038/nrc798
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Zhu, Y. (2022). Human Papillomavirus (HPV) Entry Inhibitors. In: Jiang, S., Lu, L. (eds) Virus Entry Inhibitors. Advances in Experimental Medicine and Biology, vol 1366. Springer, Singapore. https://doi.org/10.1007/978-981-16-8702-0_14
Download citation
DOI: https://doi.org/10.1007/978-981-16-8702-0_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-8701-3
Online ISBN: 978-981-16-8702-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)